REGENXBIO Inc. Available-for-sale Securities, Continuous Unrealized Loss Position, Aggregate Loss (Deprecated 2018-01-31)
REGENXBIO Inc. (RGNX) reported Available-for-sale Securities, Continuous Unrealized Loss Position, Aggregate Loss (Deprecated 2018-01-31) of $468.00 thousand for the 3-month period ending 2018-03-31, per its 10-Q filed 2018-05-08.
Discontinued › Notes › Investments
us-gaap:AvailableForSaleSecuritiesContinuousUnrealizedLossPositionAggregateLosses · last filed 2018-05-08
- REGENXBIO Inc. available-for-sale securities, continuous unrealized loss position, aggregate loss (deprecated 2018-01-31) for the quarter ending 2018-03-31 was $468.00K.
| Period end | Available-for-sale Securities, Continuous Unrealized Loss Position, Aggregate Loss (Deprecated 2018-01-31) 3 month | Available-for-sale Securities, Continuous Unrealized Loss Position, Aggregate Loss (Deprecated 2018-01-31) 12 month |
|---|---|---|
| 2018-03-31 | $468.00K 10-Q · filed 2018-05-08 | |
| 2017-12-31 | $282.00K 10-Q · filed 2018-05-08 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Entera Bio Ltd. (ENTX) | $0.485B | ||
| Tectonic Therapeutic, Inc. (TECX) | United States | $0.469B | -7.68 |
| Autolus Therapeutics plc (AUTL) | $0.506B | -1.52 | |
| Eikon Therapeutics, Inc. (EIKN) | United States | $0.446B | |
| Kyverna Therapeutics, Inc. (KYTX) | United States | $0.434B | -3.60 |
| Editas Medicine, Inc. (EDIT) | United States | $0.424B | -4.29 |
| Scribe Therapeutics, Inc. (SCTX) | United States | $0.410B | |
| Prime Medicine, Inc. (PRME) | United States | $0.557B | -3.54 |
| Zura Bio Ltd (ZURA) | $0.398B | -6.56 | |
| Surrozen, Inc./DE (SRZN) | United States | $0.395B |